In a report released today, Joseph Stringer from Needham maintained a Buy rating on Vaxcyte, with a price target of $90.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Stringer has given his Buy rating due to a combination of factors including the initiation of the Phase 3 pivotal trial for Vaxcyte’s pneumococcal conjugate vaccine, VAX-31. The trial’s design aligns with previous management guidance and expectations, which provides confidence in the company’s strategic direction. The trial will compare VAX-31 directly against existing standard-of-care vaccines, Capvaxive and Prevnar20, in a non-inferiority study, which could potentially demonstrate VAX-31’s competitive edge. The anticipated topline data from this trial, expected in the fourth quarter of 2025, is a significant milestone that could influence the company’s market position. Overall, the progress of this pivotal trial and its potential implications for Vaxcyte’s product pipeline underpin the Buy rating.
According to TipRanks, Stringer is a 5-star analyst with an average return of 23.7% and a 47.65% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Ionis Pharmaceuticals.